A cost of illness analysis of hepatocellular carcinoma for the Greek healthcare setting
Gastroenterology and Hepatology from Bed to Bench,
Vol. 13 No. 3 (2020),
2 June 2020
,
Page 219-222
https://doi.org/10.22037/ghfbb.v13i3.1905
Abstract
Aim: To estimate the cost per patient for hepatocellular carcinoma in Greece, a setting that is currently facing financial constraints.
Background: Hepatocellular carcinoma patient management strategies are associated with significant costs. Despite this, patient level data on healthcare resource use and cost-of-illness analyses of hepatocellular carcinoma remain rather scarce in the international literature.
Methods: 123 patients diagnosed with hepatocellular carcinoma and followed in a specialised clinic of a tertiary hospital in Greece formed the basis of the analysis. Detailed resource use data were derived from the medical records of each patient. Data were recorded from the first encounter of the patient with the facility until a fatal endpoint or until the last day of follow up. Patients that were lost to follow-up were excluded from the analysis. Calculations follow a third-party payer perspective, according to official prices and tariffs.
Results: The average cost per patient was estimated at 12,119.1 Euros (SD: 14,670.3) (21,375.1 PPP USD) for the average follow-up period and 10,241.5 Euros (18,063.5 PPP USD) per year. Median costs per month of follow-up according to underlying disease were 1,218.1, 1,376.8, 1,521.3 and 686.9 Euros (2,148.4, 2,428.3, 2,683.2 and 1,211.5 PPP USD) for patients with alcoholic steatohepatitis, hepatitis B, hepatitis C and non-alcoholic fatty liver disease, respectively.
Conclusion: Hepatocellular carcinoma represents a heavy toll, both from the clinical as well as from the economic perspective, especially for a setting in “dire straits”. Interventions towards reducing the incidence and, subsequently, the cost of HCC are imperative.
Keywords: Cost-of-illness, Hepatocellular cancer, Economic evaluation.
(Please cite as: Athanasakis K, Pliarchopoulou F, Naoum V, Psarrakis C, Tziolos N, Marantos T, et al. A cost of illness analysis of hepatocellular carcinoma for the Greek healthcare setting. Gastroenterol Hepatol Bed Bench 2020;13(3):219-222).
- Cost-of-illness
- hepatocellular cancer
- economic evaluation
- direct cost
How to Cite
References
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 Eur J Cancer 2018;103:356-87.
Kaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, et al. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clin Gastroenterol Hepatol 2018;16:106-14.
Abergel A, Rotily M, Branchoux S, Akremi R, de Léotoing L, Vainchtock A, et al. Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study). Clin Res Hepatol Gastroenterol 2016;40:340-8.
Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening-a systematic review. Risk Manag Healthc Policy 2012;5:49-54.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Third Edition. New York: Oxford University Press; 2005.
OECD. PPPs and exchange rates (database). Available at https://stats.oecd.org/Index.aspx?DataSetCode=SNA_TABLE4# (Accessed 19 March 2020)
White LA, Menzin J, Korn JR, Friedman M, Lang K, Ray S. Medical Care Costs and Survival Associated With Hepatocellular Carcinoma Among the Elderly. Clin Gastroenterol Hepatol 2012;10:547-54.
Eurostat. Average gross annual earnings in industry and services, by sex (database). Available at https://ec.europa.eu/eurostat/databrowser/view/tps00175/default/table?lang=en (Accessed 17 November 2019).
Gondek K, Lang K, Danchenko N, Shah S, Anderson S, Thompson D. Economic costs of hepatocellular carcinoma in the United States. J Clin Oncol 2008;26:6555.
Kaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, et al. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clin Gastroenterol Hepatol 2018;16:106-14.
Nguang SH, Wu CK, Liang CM, Tai WC, Yang SC, Ku MK, et al. Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan. Int J Environ Res Public Health 2018;15:2655.
Girgis A, Lambert SD. Cost of informal caregiving in cancer care. Cancer Forum 2017;41:16-20.
- Abstract Viewed: 58 times
- PDF Downloaded: 55 times